ESTRADOT (oestradiol), Estalis
Continuous and Sequi (oestradiol/
norethisterone acetate) hormone
replacement therapy patches are
now available on the
Pharmaceutical Benefits Scheme as
a first-line treatment for menopause.
The patches are designed to
manage the short term symptoms
associated menopause, and to also
prevent bone density loss in
postmenopausal women who are at
increased risk of future osteoporotic
fractures and are intolerant of, or
contraindicated for, other medicinal
products approved for the prevention
of bone mineral density loss.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Apr 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Apr 10
MAYNE Pharma Group Limited has filed a patent infringement suit against Sun Pharmaceutical Industries Ltd and Inc., in the United States District Court, according to yesterday’s ASX announcement.
PHARMACY Connect 2024 conference will feature a provocative ‘Great Debate’ during the Harm Minimisation Workshop on Thu 05 Sep at the Hyatt Regency in Sydney.
LTR Pharma Limited has successfully raised $10.5 million through a share placement to sophisticated and new institutional investors, significantly surpassing initial demand.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.